Very recently, in a cell-based model of tauopathies, recapitulating the abnormal deposition of phosphorylated tau protein, characteristic of several neurodegenerative disorders, the CK2 inhibitor TBB was identified as a potential drug candidate for its efficacy against tau hyperphosphorylation and oligomerization processes.185. Here, MAPT is linked to tauopathy.